[{"address1": "8, rue de la Croix Jarry", "city": "Paris", "zip": "75013", "country": "France", "phone": "33 1 81 69 16 00", "fax": "33 1 81 69 16 06", "website": "https://www.cellectis.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.", "fullTimeEmployees": 216, "companyOfficers": [{"maxAge": 1, "name": "Dr. Andre  Choulika Ph.D.", "age": 58, "title": "Co-Founder, CEO & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 876597, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David j. d. Sourdive Ph.D.", "age": 56, "title": "Deputy CEO, Executive VP of CMC & Manufacturing and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 557838, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arthur  Stril", "age": 34, "title": "Interim Chief Financial Officer", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Valerie  Cros", "title": "Principal Financial Officer & Principal Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Charles Epinat", "title": "Chief Technological Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philippe  Duchateau Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marie-Bleuenn  Terrier", "age": 41, "title": "General Counsel & Secretary of the Board of Directors", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Pascalyne  Wilson", "title": "Director of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kyung  Nam-Wortman", "age": 53, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephan  Reynier M.Sc.", "age": 54, "title": "Chief Regulatory & Pharmaceutical Compliance Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.3, "open": 2.32, "dayLow": 2.24, "dayHigh": 2.32, "regularMarketPreviousClose": 2.3, "regularMarketOpen": 2.32, "regularMarketDayLow": 2.24, "regularMarketDayHigh": 2.32, "beta": 3.228, "forwardPE": -3.289855, "volume": 12301, "regularMarketVolume": 12301, "averageVolume": 55275, "averageVolume10days": 26750, "averageDailyVolume10Day": 26750, "marketCap": 227213376, "fiftyTwoWeekLow": 0.963, "fiftyTwoWeekHigh": 3.774, "priceToSalesTrailing12Months": 11.571856, "fiftyDayAverage": 2.12072, "twoHundredDayAverage": 2.62425, "currency": "USD", "enterpriseValue": 170875360, "floatShares": 71462852, "sharesOutstanding": 100094000, "sharesShort": 395432, "sharesShortPriorMonth": 443103, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.004, "heldPercentInsiders": 0.09387, "heldPercentInstitutions": 0.14769, "shortRatio": 5.77, "shortPercentOfFloat": 0.0049, "bookValue": 1.485, "priceToBook": 1.5286195, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -78905000, "trailingEps": -1.23, "forwardEps": -0.69, "enterpriseToRevenue": 8.703, "enterpriseToEbitda": -2.208, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CLLS", "underlyingSymbol": "CLLS", "shortName": "Cellectis S.A.", "longName": "Cellectis S.A.", "firstTradeDateEpochUtc": 1427203800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a7dc8288-eba8-3f16-a312-d116920d6e16", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.27, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 7.0, "targetMedianPrice": 6.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 149042000, "totalCashPerShare": 1.489, "ebitda": -77395000, "totalDebt": 89702000, "quickRatio": 1.099, "currentRatio": 1.916, "totalRevenue": 19635000, "debtToEquity": 60.361, "revenuePerShare": 0.278, "returnOnAssets": -0.17299, "returnOnEquity": -0.64368, "freeCashflow": -46982124, "operatingCashflow": 51488000, "revenueGrowth": 3.749, "grossMargins": 0.96246004, "operatingMargins": -1.8111099, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]